fda warning letters compounded semaglutide tirzepatide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Issues Warning Letters to

CDT more than 2 years: 41 patients out of 41 (100%) were alive at the end of the study

They watch continuation applications at the USPTO

Which is part of why a peptide first pulled out of human plasma back in 1973 still keeps turning up in anti-aging conversations five decades later

By prioritizing high-absorption, clean ingredients, and consistent habits, you can support your cellular health and resilience for the long term

But several factors work against this natural recovery process, including age (collagen production drops roughly 1% per year after age 20), the amount of weight lost (more than 50 pounds creates significantly more laxity), how long the excess weight was carried, sun damage history, smoking, genetics, and the speed at which the weight came off